Novartis Builds On Its Legacy With Scemblix Approval For CML
US FDA approval means a new commercial opportunity in CML, where despite the success of older medicines, patients still fail on therapy.
You may also be interested in...
CEO Vas Narasimhan committed to delivering compound annual growth of 4% from 2020-2026, driven by newer brands plus some pipeline assets.
Phase III data for asciminib suggest it could provide a new avenue of therapy for chronic myeloid leukemia patients who are running out of treatment options.
India’s Sun Pharma has launched its generic version of Novartis' blockbuster anticancer Gleevec in the US at savings of around 30%, putting the spotlight on the specialty segment which is probably, for the first time, witnessing genericization of such a high cost therapy.